Journal Browser

► Journal Browser

Special Issue "Pharmacokinetics, Pharmacodynamics and Drug Interactions"

Share This Special Issue

Special Issue Editor

E-Mail Website
Guest Editor

York College & Graduate Center, City University of New York, New York, NY, USA
Interests: pharmacokinetics; herb/food/drug-drug interaction; pharmacokinetics and pharmacodynamics modeling and simulation; drug-metabolizing enzymes and transporters; PBPK in special populations

Special Issue Information

Dear Colleagues,

Pharmacokinetics describes a drug’s absorption, distribution, metabolism and excretion and pharmacodynamics describes what a drug does to the body. Those are critical steps to understanding a drugs’ efficacy and safety. Several intrinsic and extrinsic factors could alter a drug’s pharmacokinetic and pharmacodynamics, including other drugs/food and natural products. Drug interactions may increase the action, cause the drug less effective, or have unexpected side effects.

This Special Issue will cover manuscripts that describe the results of basic, translational and clinical research that contribute significant and novel information on pharmacokinetics, pharmacodynamics and drug interactions. Areas include innovative mechanisms, approaches, and modeling and simulation. Original research articles, review articles, or commentaries are welcomed.

Dr. Zhu Zhou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

pharmacokinetics
pharmacodynamics
drug metabolism
drug interaction
PK/PD modeling and simulation

Published Papers (1 paper)

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Open AccessArticle

Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects

and

Pharmaceutics 2023, 15(2), 549; https://doi.org/10.3390/pharmaceutics15020549 - 07 Feb 2023

Viewed by 1047

Abstract

Acid-reducing agents are commonly used for the prevention of aspirin-induced gastrointestinal complications such as peptic ulcers. As a novel potassium-competitive acid blocker, fexuprazan is expected to prevent aspirin-induced gastrointestinal complications. This randomized, open-label study aimed to evaluate the pharmacodynamic and pharmacokinetic interactions between aspirin and fexuprazan in healthy Koreans. Subjects randomized to the aspirin group received 500 mg aspirin in combination with 80 mg fexuprazan. For the fexuprazan group, fexuprazan 80 mg was administered alone and then in combination with aspirin 500 mg. Platelet aggregation inhibited by aspirin and the pharmacokinetic parameters of aspirin and fexuprazan were compared between monotherapy and combination therapy. A total of 22 subjects completed the study. The platelet aggregation-inhibitory activity and systemic exposure to aspirin were not significantly affected by fexuprazan coadministration. The systemic exposure of fexuprazan was decreased up to 20% by aspirin coadministration, which was not regarded as clinically meaningful considering the previously reported exposure–response relationship. In conclusion, there were no clinically relevant pharmacodynamic or pharmacokinetic interactions between aspirin and fexuprazan. This finding suggests the potential of fexuprazan for the prevention of aspirin-induced gastrointestinal complications, serving as a baseline for optimizing its therapeutic application with aspirin. Full article

(This article belongs to the Special Issue Pharmacokinetics, Pharmacodynamics and Drug Interactions)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Pharmacokinetics, Pharmacodynamics and Drug Interactions"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (1 paper)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI